PharmiWeb Today Story
Acquisition includes world-leading in vivo delivery platform with potential to
transform cell therapy
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current process which takes weeks.
ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases. This approach enables cell therapies to be administered through a simple IV injection and without the need for immune cell depletion.
Traditional cell therapies require cells to be removed from a patient, genetically modified outside the body, and then readministered to the patient as a medicine after immune cell depletion, typically taking weeks. By engineering immune cells directly within the patient’s body, the EsoBiotec in vivo approach has the potential to address many of the barriers associated with traditional cell therapies, reducing complexities and manufacturing timelines, thereby increasing access for patients.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “We are excited about the acquisition of EsoBiotec…
Read More...
Articles

What Does a Pharmaceutical Account Manager Do?
04-Mar-2025

Top 10 Highest Paying Pharma Jobs in 2025
18-Feb-2025

The Impact of AI on Pharmaceutical Sales
13-Feb-2025

What Does a Medical Science Liaison Do?
18-Sep-2023
Featured Events

-
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
Pharma USA 2022
16-Mar-2022 - 17-Mar-2022 -
AI in Healthcare Summit Boston 2022
13-Oct-2022 - 14-Oct-2022 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023 -
Reuters Events: Pharma USA 2023
28-Mar-2023 - 29-Mar-2023
News

-
2025 PM Society Awards – Winners Announced
17-Mar-2025 -
Atrial Fibrillation Surgery Devices Market to Surp…
17-Mar-2025 -
AstraZeneca to acquire EsoBiotec to advance cell t…
17-Mar-2025 -
AstraZeneca enters license agreement with Alteogen…
17-Mar-2025 -
Eneboparatide met primary endpoint of normalising…
17-Mar-2025 -
Novo Nordisk ABPI membership restored
17-Mar-2025